Impact of oxaliplatin and a novel DACH-platinum complex in the gene expression of HCT116 colon cancer cells

Oncology Reports

Volumn 20, Issue 5, 2008, Pages 1269-1276

  Pang, Siu Kwong ^a   Yu, Chun Wing ^a   Guan, Huaji ^a   Au Yeung, Steve C F ^a   Ho, Yee Ping ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Colon cancer; Demethylcantharidin; Diaminocyclohexane platinum complexes; Gene expression; Oxaliplatin

Indexed keywords

BETA3 INTEGRIN BINDING PROTEIN; BINDING PROTEIN; BRCA1 PROTEIN; DNA; DNA BASE; OXALIPLATIN; PLATINUM 1,2 DIAMINOCYCLOHEXANE; SURVIVIN; UNCLASSIFIED DRUG; (DIAMINOCYCLOHEXANE)(DEMETHYLCANTHARIDIN)PLATINUM(II); ANTINEOPLASTIC AGENT; CANTHARIDIN; DEMETHYLCANTHARIDIN; DRUG DERIVATIVE; PLATINUM COMPLEX; PLATINUM DERIVATIVE;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL CYCLE REGULATION; CELL STRAIN HCT116; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA STRAND; DNA SYNTHESIS; DRUG DESIGN; DRUG STRUCTURE; EXCISION REPAIR; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MISMATCH REPAIR; MITOSIS SPINDLE; PRIORITY JOURNAL; UPREGULATION; COLON TUMOR; DNA MICROARRAY; DRUG EFFECT; GENETICS; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANTHARIDIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; GENE EXPRESSION; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGANOPLATINUM COMPOUNDS; PLATINUM COMPOUNDS;

EID: 58149352925     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000140     Document Type: Article

References (26)

1. Raymond E, Faivre S, Chaney S, Woynarowski J and Cvitkovic E: Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1: 227-235, 2002.
2. Massicot F, Dutertre-Catella H, Pham-Huy C, Liu XH, Due HT and Warnet JM: In vitro assessment of renal toxicity and inflammatory events of two protein phosphatase inhibitors cantharidin and nor-cantharidin. Basic Clin Pharmacol Toxicol 96: 26-32, 2005.
3. Yu CW, Li KKW, Pang SK, Au-Yeung SCF and Ho YP: Anti-cancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1,2-diaminocyclohexane. Bioorg Med Chem Lett 16: 1686-1691, 2006.
4. Pang SK, Yu CW, Au-Yeung SCF and Ho YP: DNA damage induced by novel demethylcantharidin-integrated platinum anti-cancer complexes. Biochem Biophys Res Commun 363: 235-240, 2007.
5. Chen YJ, Shieh CJ, Tsai TH, Kuo CD, Ho LT, Liu TY and Liao HF: Inhibitory effect of norcantharidin, a derivative compound from blister beetles, on tumor invasion and metastasis in CT26 colorectal adenocarcinoma cells. Anti-cancer Drugs 16: 293-299, 2005.
6. Li JL, Cai YC, Liu XH and Xian LJ: Norcantharidin inhibits DNA replication and induces apoptosis with the cleavage of initiation protein Cdc6 in HL-60 cells. Anti-cancer Drugs 17: 307-314, 2006.
7. Chen YN, Chen JC, Yin SC, Wang GS, Tsauer W, Hsu SF and Hsu SL: Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer 100: 158-163, 2002.
8. Bonness K, Aragon IV, Rutland B, Ofori-Acquah S, Dean NM and Honkanen RE: Cantharidin-induced mitotic arrest is assocated with the formation of aberrant mitotic spindles and lagging chromosomes resulting, in part, from the suppression of PP2Aa. Mol Cancer Ther 5: 2727-2736, 2006.
9. Kikuchi K, Taniguchi Y, Hatanaka A, Sonoda E, Hochegger H, Adachi N, Matsuzaki Y, Koyama H, van Gent DC, Jasin M and Takeda S: Fen-1 facilitates homologous recombination by removing divergent sequences at DNA break ends. Mol Cell Biol 25: 6948, 2005.
10. Liu S, Calderwood DA and Ginsberg MH: Integrin cytoplasmic domain-binding proteins. J Cell Sci 113: 3563-3571, 2000.
11. Ashman LK: The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 31: 1037-1051, 1999.
12. Widlak P, Pietrowska M and Lanuszewska J: The role of chromatin proteins in DNA damage recognition and repair. Histochem Cell Biol 125: 119-126, 2006.
13. Müller S, Ronfani L and Bianchi ME: Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 255: 332-343, 2004.
14. Wang D and Lippard SJ: Cellular processing of platinum anti-cancer drugs. Nat Rev Drug Discov 4: 307-320, 2005.
15. Efferth T, Rauh R, Kahl S, Tomicic M, Böchzelt H, Tome ME, Briehl MM, Bauer R and Kaina B: Molecular modes of action of cantharidin in tumor cells. Biochem Pharmacol 69: 811-818, 2005.
16. Jung Y and Lippard SJ: Direct cellular responses to platinum-induced DNA damage. Chem Rev 107: 1387-1407, 2007.
17. Friedberg EC: Reversible monoubiquitination of PCNA: a novel slant on regulating translesion DNA synthesis. Mol Cell 22: 150-152, 2006.
18. Saxena S and Dutta A: Geminin-Cdt1 balance is critical for genetic stability. Mutat Res 569: 111-121, 2005.
19. Shukla A, Navadgi VM, Mallikarjuna K and Rao BJ: Interaction of hRad51 and hRad52 with MCM complex: a cross-talk between recombination and replication proteins. Biochem Biophys Res Commun 329: 1240-1245, 2005.
20. Malumbres M and Barbacid M: Mammalian cyclin-dependent kinases. Trends Biochem Sci 30: 630-641, 2005.
21. Taylor WR and Stark GR: Regulation of the G2/M transition by p53. Oncogene 20: 1803-1815, 2001.
22. Taylor SS, Scott MIF and Holland AJ: The spindle checkpoint: a quality control mechanism which ensures accurate chromosome segregation. Chromosome Res 12: 599-616, 2004.
23. Hoffmann I: Protein kinase involved in mitotic spindle checkpoint regulation. In: Cell Cycle Regulation: Results and Problems in Cell Differentiation. Kaldis P (ed). Vol. 4, Springer, New York, p31-63, 2006.
24. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R and Kroemer G: Cell death by mitotic catastrophe: a molecular definition. Oncogene 23: 2825-2837, 2004.
25. Damiano JS: Integrins as novel drug targets for overcoming innate drug resistance. Curr Cancer Drug Targets 2: 37-43, 2002.
26. Deng CX: BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 34: 1416-1426, 2006.